^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GSPT1 degrader

    Related drugs:
    Apply
    Study of Oral MRT-2359 in Selected Cancer Patients (MRT-2359-001) (NCT05546268)
    Phase 1/2
    Monte Rosa Therapeutics, Inc
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    10/12/2022
    Primary completion :
    05/01/2026
    Completion :
    11/01/2027
    MYC • MYCN
    |
    MYCN amplification • MYC expression
    |
    Xtandi (enzalutamide) • fulvestrant • MRT-2359
    Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors (NCT05511844)
    Phase 1
    Orum Therapeutics USA, Inc.
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    10/03/2022
    Primary completion :
    04/01/2025
    Completion :
    10/01/2025
    HER-2
    |
    ORM-5029